Advertisement

Treatment of Severe C. difficile–Associated Diarrhea: Vancomycin vs. Metronidazole

Summary and Comment |
August 8, 2007

Treatment of Severe C. difficile–Associated Diarrhea: Vancomycin vs. Metronidazole

  1. Neil M. Ampel, MD

Among patients with severe disease, the clinical cure rate was significantly higher with vancomycin than with metronidazole.

  1. Neil M. Ampel, MD

Clostridium difficile is the most common cause of nosocomial diarrhea in acute-care settings. Until now, the two available therapies for C. difficile–associated diarrhea (CDAD), vancomycin and metronidazole, had been compared in only two prospective, randomized trials — neither of them blinded or placebo-controlled. Moreover, these studies did not distinguish between mild and severe CDAD.

Now, researchers in Illinois have conducted a single-center, double-blind study in which patients with diarrhea and either C. difficile toxin A in the stool or documented pseudomembranous colitis were randomized to receive vancomycin 125 mg or metronidazole 250 mg, each plus placebo, four times daily. Patients were stratified by CDAD severity, with severe disease defined as ≥2 points (1 point each for age >60 years, temperature >38.3°C, serum albumin level <2.5 mg/dL, or peripheral white blood cell count >15,000 cells/mm3; 2 points each for endoscopic evidence of pseudomembranous colitis or ICU treatment). Cure was defined as resolution of diarrhea by day 6 of treatment and a negative C. difficile stool toxin assay at days 6 and 10 of treatment.

A total of 150 participants completed 10 days of therapy; 69 of them had severe CDAD. For patients with severe disease, the cure rate was significantly higher with vancomycin than with metronidazole (97% vs. 76%; P=0.02). However, for patients with mild CDAD, the difference was much smaller (98% vs. 90%; P=0.36). No significant differences were seen in relapse rates or adverse events between the two therapies. Factors significantly associated with metronidazole treatment failure were serum albumin level <2.5 mg/dL, presence of pseudomembranous colitis, and ICU admission.

Comment

These findings support several other observations that metronidazole has become increasingly less effective in the treatment of CDAD (see Journal Watch Infectious Diseases Jul 8 2005). However, metronidazole is still currently recommended as first-line therapy by several society guidelines, principally because it is less expensive than vancomycin and because of concern that using vancomycin might increase the prevalence of vancomycin-resistant organisms in the intestinal lumen. Such recommendations should be reevaluated in light of the accumulating data.

Citation(s):

Reader Comments (2)

S.E. Toews

I was diagnosed with C-diff on June 22,2009 after taking antibiotics. I have presently had two rounds of Flagyl and 5 days of Cholestyramine with no help. I will begin Vancomycin on Monday and trust it will help.

Competing interests: What further help is there?

Janet baxter

Hello, I contracted C-diff due to taking high doses antibiotics.

So far my dr has given me 2 rounds of flagyl and 1 round of vancomycin.

The c-diff is still positive.

Is there anything else you recommend to get rid of C-diff?

Competing interests: None declared

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement